Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial

The benefit of high-flow nasal cannula oxygen (high-flow oxygen) in terms of intubation and mortality in patients with respiratory failure due to COVID-19 is controversial. To determine whether the use of high-flow oxygen, compared with standard oxygen, could reduce the rate of mortality at day 28 i...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	JAMA : the journal of the American Medical Association Ročník 328; číslo 12; s. 1212
Hlavní autori:	Frat, Jean-Pierre, Quenot, Jean-Pierre, Badie, Julio, Coudroy, Rémi, Guitton, Christophe, Ehrmann, Stephan, Gacouin, Arnaud, Merdji, Hamid, Auchabie, Johann, Daubin, Cédric, Dureau, Anne-Florence, Thibault, Laure, Sedillot, Nicholas, Rigaud, Jean-Philippe, Demoule, Alexandre, Fatah, Abdelhamid, Terzi, Nicolas, Simonin, Marine, Danjou, William, Carteaux, Guillaume, Guesdon, Charlotte, Pradel, Gaël, Besse, Marie-Catherine, Reignier, Jean, Beloncle, François, La Combe, Béatrice, Prat, Gwénaël, Nay, Mai-Anh, de Keizer, Joe, Ragot, Stéphanie, Thille, Arnaud W
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 27.09.2022
Predmet:	Cannula - adverse effects COVID-19 - complications COVID-19 - mortality COVID-19 - therapy Female Humans Male Masks Middle Aged Oxygen - administration & dosage Oxygen Inhalation Therapy - adverse effects Respiratory Insufficiency - etiology Respiratory Insufficiency - mortality Respiratory Insufficiency - therapy
ISSN:	1538-3598, 1538-3598
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	The benefit of high-flow nasal cannula oxygen (high-flow oxygen) in terms of intubation and mortality in patients with respiratory failure due to COVID-19 is controversial. To determine whether the use of high-flow oxygen, compared with standard oxygen, could reduce the rate of mortality at day 28 in patients with respiratory failure due to COVID-19 admitted in intensive care units (ICUs). The SOHO-COVID randomized clinical trial was conducted in 34 ICUs in France and included 711 patients with respiratory failure due to COVID-19 and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen equal to or below 200 mm Hg. It was an ancillary trial of the ongoing original SOHO randomized clinical trial, which was designed to include patients with acute hypoxemic respiratory failure from all causes. Patients were enrolled from January to December 2021; final follow-up occurred on March 5, 2022. Patients were randomly assigned to receive high-flow oxygen (n = 357) or standard oxygen delivered through a nonrebreathing mask initially set at a 10-L/min minimum (n = 354). The primary outcome was mortality at day 28. There were 13 secondary outcomes, including the proportion of patients requiring intubation, number of ventilator-free days at day 28, mortality at day 90, mortality and length of stay in the ICU, and adverse events. Among the 782 randomized patients, 711 patients with respiratory failure due to COVID-19 were included in the analysis (mean [SD] age, 61 [12] years; 214 women [30%]). The mortality rate at day 28 was 10% (36/357) with high-flow oxygen and 11% (40/354) with standard oxygen (absolute difference, -1.2% [95% CI, -5.8% to 3.4%]; P = .60). Of 13 prespecified secondary outcomes, 12 showed no significant difference including in length of stay and mortality in the ICU and in mortality up until day 90. The intubation rate was significantly lower with high-flow oxygen than with standard oxygen (45% [160/357] vs 53% [186/354]; absolute difference, -7.7% [95% CI, -14.9% to -0.4%]; P = .04). The number of ventilator-free days at day 28 was not significantly different between groups (median, 28 [IQR, 11-28] vs 23 [IQR, 10-28] days; absolute difference, 0.5 days [95% CI, -7.7 to 9.1]; P = .07). The most common adverse events were ventilator-associated pneumonia, occurring in 58% (93/160) in the high-flow oxygen group and 53% (99/186) in the standard oxygen group. Among patients with respiratory failure due to COVID-19, high-flow nasal cannula oxygen, compared with standard oxygen therapy, did not significantly reduce 28-day mortality. ClinicalTrials.gov Identifier: NCT04468126.
Bibliografia:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	1538-3598 1538-3598
DOI:	10.1001/jama.2022.15613